Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin (CMR-IMPACT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Wake Forest Baptist Health
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Chadwick Miller, Wake Forest Baptist Health
ClinicalTrials.gov Identifier:
NCT01931852
First received: August 26, 2013
Last updated: May 29, 2014
Last verified: May 2014

August 26, 2013
May 29, 2014
September 2013
December 2016   (final data collection date for primary outcome measure)
Reduction in composite death, nonfatal myocardial infarction (MI), and cardiac related readmission [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces the composite of death, nonfatal MI, and cardiac-related hospital readmission over time.
Same as current
Complete list of historical versions of study NCT01931852 on ClinicalTrials.gov Archive Site
  • Reduction in invasive angiography. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces invasive angiography.
  • Reduction in coronary revascularization. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces coronary revascularization.
  • Reduction in recurrent cardiac testing. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces recurrent cardiac testing.
  • Reduction in cardiac-related ED visits. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces cardiac-related ED visits.
Same as current
Not Provided
Not Provided
 
Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin
Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

The broad, long-term objective is to improve outcomes by optimizing healthcare delivery processes for patients with detectable to elevated serum troponin. This clinical trial involving emergency department (ED) patients with intermediate to high-risk chest pain and detectable to minimally elevated serum troponin within 6 hours of evaluation.

In the evaluation of patients with possible acute coronary syndrome, serum troponin measurement is a critical determinant of myocardial necrosis. The recent implementation of high-sensitivity troponin assays allows detection of lower levels of serum troponin than possible with less sensitive predecessors. As a result, 30% more patients are diagnosed with myocardial injury but the optimal management of these patients is unclear. Guidelines from the American Heart Association and American College of Cardiology recommend an invasive management strategy (Class 1a) but acknowledge that data supporting an invasive strategy were based on less sensitive troponin assays than those available today. Clinical trials of an invasive strategy in patients with detectable to minimally elevated troponin values demonstrate conflicting results. Observational data suggest aggressive medical therapy rather than increased use of revascularization drives improved outcomes in these patients. Meanwhile, these patients with minimally elevated serum troponin values have experienced a near doubling in the rate of invasive angiography. In short, it is uncertain whether patients with detectable to minimally elevated troponin results benefit from current invasive-based care strategies. As an alternative, cardiac magnetic resonance (CMR) imaging is highly accurate for detecting significant coronary disease and the need for coronary revascularization.

Objectives: The broad, long-term objective is to improve outcomes by optimizing healthcare delivery processes for patients with detectable to elevated serum troponin. To achieve this goal, we propose a clinical trial (n=312) involving emergency department patients with intermediate to high-risk chest pain and detectable to minimally elevated serum troponin within 6 hours of evaluation.

Methods: Participants will be randomized to one of two care strategies: a) invasive-based guideline-adherent strategy, or b) CMR-guided. Outcomes will be assessed over an average of 2.3 years. The specific aims of this proposal are 1) Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces the composite of death, nonfatal myocardial infarction, and cardiac-related hospital readmission over the study duration, and 2) Test whether a CMR-guided strategy (versus invasive-based guideline-adherent strategy) reduces invasive angiography, coronary revascularization, recurrent cardiac testing, and cardiac-related emergency department visits.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
  • Acute Coronary Syndrome
  • Chest Pain
  • Procedure: Cardiac MRI
    Participants in the CMR-guided care group will receive a cardiac MRI.
    Other Names:
    • CMR
    • Cardiac Magnetic Resonance Imaging
  • Other: ACC/AHA Guideline adherent care
    Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations.
  • Experimental: CMR-guided care
    Participants in this group will receive a cardiac MRI.
    Intervention: Procedure: Cardiac MRI
  • Active Comparator: Invasive-based guideline-adherent care
    Participants will receive care adherent with current ACC/AHA guideline recommendations.
    Intervention: Other: ACC/AHA Guideline adherent care

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
312
May 2018
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age greater than or equal to 21 years of age at the time of enrollment
  • Symptoms consistent with acute coronary syndrome
  • At least 1 troponin > lower limit of detection and ≤1.0 ng/ml within 6 hours of the initial ED evaluation

Exclusion Criteria:

  • Any troponin >1.0 ng/ml at the time of consent
  • New ST-segment elevation (≥ 1 mV) or depression (≥ 2 mV)
  • Hemodynamic instability (symptomatic systolic BP <90 mmHg, dysrhythmia)
  • Ongoing, unrelieved symptoms thought to represent cardiac ischemia and requiring immediate cardiac catheterization
  • Inducible cardiac ischemia without subsequent revascularization, known to the care providers at the time of assessment
  • Coronary revascularization in the past 6 months
  • Contra-indications to magnetic resonance imaging Examples: Unable to lie flat, pacemaker, defibrillator, cerebral aneurysm clips, metallic ocular foreign body, implanted devices, severe claustrophobia, pregnancy
  • Life expectancy less than 12 months
  • Increased risk for nephrogenic systemic fibrosis i. Creatinine clearance < 30 ml/min at the time of enrollment ii. clinical concern for acute kidney injury and/or acute renal failure* iii. Hepato-renal syndrome or chronic liver disease with a creatinine clearance of <60 ml/min at the time of enrollment iv. History of liver, heart, or kidney transplant

    • This may be manifested by a recent or concurrent rise in serum creatinine, or a reduction in baseline creatinine clearance.
Both
21 Years and older
No
Contact: Erin Harper, MSHS, CCRP 336-716-2059 erharper@wakehealth.edu
United States
 
NCT01931852
IRB00022322, 1R01HL118263-01A1
Yes
Chadwick Miller, Wake Forest Baptist Health
Wake Forest Baptist Health
  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Chadwick Miller, MD, MS WFBMC
Wake Forest Baptist Health
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP